GE Healthcare Blog - Cardiology, Oncology, Molecular Imaging

Treat to Target: What are the benefits of a targeted ultrasound approach?

Now online: the GE Healthcare and Abbott co-sponsored scientific Satellite Symposium at EULAR 2012: “Treat to Target: What are the benefits of a targeted ultrasound approach?”

According to the symposium chairman Paul Emery, “Imaging modalities are critical for the early diagnosis and monitoring of RA. Application of tools such as sonography in conjunction with T2T principles may further improve clinical outcomes.”

Watch the three webcasts here.

State of the art in ultrasound imaging: Today and tomorrow

According to Maria Antonietta D’Agostino, Professor of Rheumatology at the Université de Versailles St-Quentinen- Yvelines and the Rheumatology Department of Ambroise Paré, Hospital, Boulogne-Billancourt, France: 

Early diagnosis, followed by early initiation and adjustment of treatment, are essential for successful long-term management of chronic inflammatory arthritis. Sensitive and specific methods are required for detection and monitoring of disease.^1,2 Of the new imaging methods, ultrasonography (US) appears highly promising.

US is now widely used in rheumatological practice for the assessment and quantification of joint inflammation and damage especially for rheumatoid arthritis (RA). Development of semi-quantitative scoring methods, combined use of imaging technologies (e.g. live US/MRI fusion imaging), and optimal visualisation of joint involvement, both in 2D and in 3D, have all contributed to the usefulness of US for detecting changes in joint inflammation in RA. For this reason, it is important to understand whether these new imaging technologies can translate into routine clinical practice. A clinician needs to quickly assess whether active inflammation is present and whether structural damage is occurring in order to instigate appropriate therapy adjustment.^3,4

US allows clinicians to distinguish between joint effusion and synovial hypertrophy and between active and fibrotic synovial hypertrophy based on differences in echogenicity using a grayscale approach (i.e. morphology). More recently, the addition of Doppler techniques has provided more information about synovial vascularity (i.e. inflammation) and the morphology of the synovium as well as temporal changes in the synovium, reflective of the different stages of the disease. The ability to detect inflammation which is not clinically apparent (sub-clinical disease) enables us to consider a new way of detecting early arthritis and explain the apparent association between clinical improvement and radiological deterioration in patients who are in clinical remission.⁵

Learn more from Professor Maria Antonietta D’Agostino at Rheumatology congress EULAR 2012, at the GE Healthcare / Abbott co-sponsored symposium: "Treat to target: What are the benefits of using a targeted ultrasound approach?" Learn more here.

References

1. Ostergaard M, et al. Best Pract Res Clin Rheumatol 2008;22:1019–44.

2. Koski JM, et al. Ann Rheum Dis 2006;65:1590–5.

3. Naredo E, et al. Clin Exp Rheumatol 2010;28:79–82.

4. Lagnocco A, et al. Rheumatology (Oxford) 2010;50:1409–13.

5. Saleem B, et al. Ann Rheum Dis 2011;70:792–8.

Treat to target: Current thinking in RA disease management

According to Mikkel Østergaard, Professor of Rheumatology at the University of Copenhagen and Copenhagen University Hospital at Glostrup, Denmark :

The management of rheumatoid arthritis (RA) has improved dramatically over the last decade due to improved diagnostic and management strategies as well as the introduction of new therapies.

The 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification criteria for RA have enabled earlier diagnosis,¹ and clinical trials have documented the clinical and radiographic benefit of early aggressive therapy when aiming for a predefined treatment goal.^2,3 In accordance with this, new management recommendations from EULAR⁴ as well as from an international Treat-to-Target task force,⁵ have set remission as the primary treatment goal for RA in everyday clinical practice.

Now that consensus exists about remission being the appropriate treatment goal for RA, it is crucial to decide on how remission should be defined. Several definitions exist,^6,7 including the recent ACR/EULAR definition of remission in RA for clinical trials.⁸ All current definitions are based on clinical and laboratory parameters. However, modern imaging (magnetic resonance imaging [MRI] and ultrasonography [US]) in patients in clinical remission reveal that a significant number display signs of disease activity such as synovitis and/or osteitis.^9,10

Furthermore, the presence of disease activity detected by imaging techniques is related to subsequent radiographic progression.^11,12 Thus, modern imaging modalities may have an important future role in defining remission in RA.

Learn more from Professor Mikkel Østergaard at Rheumatology congress EULAR 2012, at the GE Healthcare / Abbott co-sponsored symposium: "Treat to target: What are the benefits of using a targeted ultrasound approach?"

Learn more here.

References

1. Aletaha D, et al. Ann Rheum Dis 2010;69:1580–8.

2. Grigor C, et al. Lancet 2004;364:263–9.

3. Hetland ML, et al. Arthritis Rheum 2006;54:1401–9.

4. Smolen JS, et al. Ann Rheum Dis 2010;69:964–75.

5. Smolen JS, et al. Ann Rheum Dis 2010;69:631–7.

6. Pinals RS, et al. Arthritis Rheum 1981;24:1308–15.

7. Prevoo ML, et al. Br J Rheumatol 1996;35:1101–5.

8. Felson DT, et al. Ann Rheum Dis 2011;70:404–13.

9. Brown AK, et al. Arthritis Rheum 2006;54:3761–73.

10. Gandjbakhch F, et al. J Rheumatol 2011;38:2039–44.

11. Brown AK, et al. Arthritis Rheum 2008;58:2958–67.

12. Haavardsholm EA, et al. Ann Rheum Dis 2012; (EULAR 2012 supplement).

Redefining standards of care in Rheumatoid Arthritis with a targeted ultrasound approach

According to Professor Paul Emery, Arthritis Research UK Professor of Rheumatology and Head of the Musculoskeletal Division, Leeds Instituteof Molecular Medicine, University of Leeds, UK : 

In recent years, the introduction of biological agents and application of the Treat to Target (T2T) approach¹  have made clinical remission an achievable goal for many patients with rheumatoid arthritis (RA). Once remission is attained, it is important to maintain absence of disease activity and flare for as long as possible. Available data suggest that up to 50% of patients in clinical remission may experience a disease flare within 2 years² and that increased power Doppler (PD) ultrasound activity in clinical remission is associated with disease flare,³ along with being predictive of longterm structural damage.⁴ 

As such, combining imaging with clinical assessments to monitor RA disease activity may further improve outcomes and help to guide subsequent treatment decisions.

The TURA trial has been designed to assess whether the addition of ultrasound-guided therapy to standard clinical management of RA using T2T principles can further improve outcomes in patients with stable, clinical low disease activity/remission. The primary objective is to determine whether therapy modifications guided by ultrasound findings and DAS28 scores can reduce the level of inflammation assessed by PD ultrasound compared with clinical assessment of DAS28 alone. Other key objectives are to establish whether addition of ultrasound-guided therapy can reduce radiographic progression and improve functional outcomes, and identify predictive factors for sustained remission, absence of structural damage and improvement in functional outcomes. It is hoped that results from the TURA trial will contribute to the development of new and improved disease management principles for RA.

Learn more from Professor Paul Emery at Rheumatology congress EULAR 2012, at the GE Healthcare / Abbott co-sponsored symposium: "Treat to target: What are the benefits of using a targeted ultrasound approach?". Learn more here.

References

1. S molen JS, et al. Ann Rheum Dis 2010;69:631–7.

2. Molenaar ET, et al. Arthritis Rheum 2004;50:36–42.

3. Saleem B, et al. Ann Rheum Dis 2012; 31 Jan [Epub].

4. Brown AK, et al. Arthritis Rheum 2008;58:2958–67.

Treat to target: What are the benefits of using a targeted ultrasound approach?

At EULAR 2012, the Annual European Congress of Rheumatology in Berlin join us at the GE Healthcare / Abbott co-sponsored TUI Satellite Symposium: "Treat to target: What are the benefits of using a targeted ultrasound approach?"

According to the symposium chairman Paul Emery, Arthritis Research UK Professor of Rheumatology, "Treat to Target (T2T) has revolutionised the management of rheumatoid arthritis (RA), making clinical remission a realistic goal for many patients. Imaging modalities are critical for the early diagnosis and monitoring of RA. Application of tools such as sonography in conjunction with T2T principles may further improve clinical outcomes"

Few words about TUI initiative:

Targeted Ultrasound Initiative (TUI) is an international effort led by a world-leading faculty of rheumatologists and ultrasound leads (18 experts from UK, France, Italy, Spain, Germany, Denmark, Japan, Hungary) to help increase the expertise of ultrasonography amongst a network of rheumatologists. TUI also aims to create a network of researchers to undertake multinational research to answer critical questions in the application of ultrasound to clinical practice. http://www.targetedultrasound.net/

Learn more about symposium at EULAR 2012.

Rheumatology...Advancing bone and joint health, helping improve quality of life.

More than 100 million people in Europe are affected by arthritis and/or rheumatism, making it Europe's most widespread chronic disease.¹

Every 30 seconds, a fracture occurs due to osteoporosis.²  Can this be prevented?

A new era of imaging has led to better understanding of bone and joint health. Studies show that early diagnosis and clinical management can help enhance care and contain costs.^3,4

Help enhance care standards and improve quality of life for your patients...

1.PARE Manifesto Steering Group; The PARE Manifesto: A call to Action.

2. Blanchard F, President,Report Working Group. Report on Osteoporosis in the European Community: Building Strong Bones and Preventing Fractures - Action to Prevention. European Communities, Brussels, 1998, EC Report CE-09-97-915-EN-C

3. Fit For Work? (2009) Musculoskeletal Disorders in the European Workforce, Stephen Bevan, Tatiana Quadrello, Robin McGee, Michelle Mahdon, Anna Vavrovsky, Leela Barha

4. V.P.K. Nell, K.P. Machold, G. Eberl, T.A. Stamm, M.Uffmann and J.S. Smolen, Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in Rheumatology, 2004:43:906_914

What is the new gold standard for Aortic Aneurysm Repair?

In a recent interview with Professor Stéphan Haulon*, Vascular Surgery Department, University Hospital of Lille, France, he addresses the adoption of minimally invasive endovascular aortic repair (EVAR) aided by advanced clinical imaging device solutions from GE Healthcare.

One of the key questions, “ Is open surgery for the repair of aortic aneurysms the ‘gold standard’ or is it the ‘old standard?’”

A majority of surgeons agreed open surgery is rapidly becoming the "old standard" in a debate on this question at the 2010 Joint Meeting of the Society of Vascular Surgery and the European Society for Vascular Surgery.
                                            
In an exclusive e-book “Advanced Endovascular Surgery”, Prof Haulon describes his experience using a mobile hybrid OR.

A new class of vascular surgeons is emerging in aortic repair - Thanks to major advances in the treatment of large-vessel
 aneurysms, the movement to treat vascular abnormalities using minimally invasive techniques is accelerating.
Abdominal aortic aneurysms (AAA) represent a genuine unmet medical need, affecting an estimated 5% of adults over
the age of 65 years diagnosed with this life-threatening condition. Sudden death is nearly certain for patients in the event
of a rupture, where as the risk of mortality is reduced to less than 5% in the surgical repair of the aneurysm.

 Want to know more? View the postcard videos from the 2010 Charing Cross symposium
- Advantages of mobile hybrid operating room
- Radiation study on mobile C-arms and aortic endografting

 

 

For an overview of our innovative surgery products visit our Radiology News site.

*Prof. Haulon provides consultation to GE Healthcare

 

 

 

 

A $6 billion commitment to healthcare. Better health for more people everywhere.

 
$4.5 trillion is spent on global healthcare annually. Over 100 million people fall into poverty each year from healthcare expenses. Two billion people worldwide live without even basic healthcare. Best practice care is delivered only about half the time. And that’s just the start. Add in aging populations, rising chronic diseases, and growing demand for tools tailored to local healthcare markets—and healthcare is by far one of the world’s most pressing and complex problems.
GE Healthcare is addressing global healthcare needs in very real and relevant ways. Healthymagination is about better health for more people everywhere. To that end, we’ve made a $6 billion commitment to develop innovations that will lower healthcare costs, increase healthcare access, and improve healthcare quality by 15%—goals we’re making real through diverse offerings and activities. Know more about it...

Inwestycja w ochronę zdrowia rzędu 6 miliardów dolarów. Nasz cel to poprawa opieki zdrowotnej dla większej liczby ludzi na całym świecie.

 

Na ochronę zdrowia rocznie wydaje się 4,5 biliona dolarów. Ponad 100 milionów ludzi co roku popada w niedostatek ze względu na ponoszone koszty leczenia. Dwa miliardy mieszkańców globu nie ma dostępu do nawet najbardziej podstawowych usług medycznych.
Zaledwie w połowie przypadków pacjenci otrzymują najlepsze, zgodne ze standardami leczenie. Ale to nie wszystko. Dodajmy do tego starzenie się populacji, nasilające się występowanie chorób przewlekłych i rosnące zapotrzebowanie na narzędzia dostosowane do potrzeb miejscowych rynków usług medycznych. Już samo to krótkie zestawienie wskazuje, że opieka zdrowotna jest jednym z najtrudniejszych i złożonych problemów.
Firma GE Healthcare kieruje się globalnymi potrzebami w zakresie opieki zdrowotnej, działając w bardzo namacalny sposób i reagując w zależności od zapotrzebowania.
Strategia healthymagination oznacza poprawę stanu zdrowia większej liczby ludzi na całym świecie. Dowiedz sie wiecej tutaj...

Helping you address the challenges in Coronary Artery Disease

Have you joined our booth or symposia at ESC 2010?

You are welcome to share your comments and questions with us.

You can still view our program and products presented at the booth on our ESC 2010.

See also our complete Cardiology ESC.